Demographics | Group 1 (⩽50 years) | Group 2 (51–64 years) | Group 3 (⩾65 years) |
---|---|---|---|
No of patients | 81 | 254 | 115 |
Males (%) | 64 (79%) | 234 (92%) | 96 (83%) |
Mean (SD) age (years) | 39 (11) | 58 (4) | 70 (3) |
Range | 7–50 | 51–64 | 65–78 |
Mean (SD) follow up (months) | 30 (24) | 30 (26) | 19 (20) |
Range | < 1–114 | < 1–112 | < 1–107 |
Underlying disease | |||
CAD | 36 (44%) | 188 (74%) | 86 (75%) |
DCM | 18 (22%) | 42 (17%) | 16 (14%) |
R/LVD | 5 (6%) | 8 (3%) | 6 (5%) |
Other | 22 (27%) | 16 (6%) | 7 (6%) |
ACVB | 7 (9%) | 49 (19%) | 24 (21%) |
Vessel disease | |||
0 | 40 (49%) | 72 (28%) | 31 (27%) |
1 vessel | 14 (17%) | 49 (19%) | 27 (23%) |
2 vessels | 10 (12%) | 66 (26%) | 29 (25%) |
3 vessels | 17 (21%) | 67 (26%) | 28 (24%) |
Left ventricular ejection fraction | |||
Mean (SD), % | 36 (16) | 32 (13) | 39 (15) |
Range | 12–85 | 12–85 | 15–77 |
<40% | 49 (60%) | 187 (74%) | 61 (53%) |
⩾40% | 32 (40%) | 67 (26%) | 54 (47%) |
Arrhythmia history | |||
No arrhythmias | 3 (4%) | 8 (3%) | 4 (3%) |
SMVT | 16 (20%) | 90 (35%) | 38 (33%) |
VF | 35 (43%) | 59 (23%) | 32 (28%) |
SMVT+VF | 27 (33%) | 97 (38%) | 40 (35%) |
Heart failure | |||
NYHA I | 24 (30%) | 26 (10%) | 6 (5%) |
NYHA II | 19 (23%) | 109 (43%) | 44 (38%) |
NYHA II-III | 20 (25%) | 72 (28%) | 34 (30%) |
NYHA III | 18 (22%) | 47 (19%) | 31 (27%) |
No of failed antiarrhythmic drugs (SD) | 3 (2) | 3 (2) | 3 (2) |
Range | 1–8 | 1–13 | 1–11 |
CAD, coronary artery disease; DCM, dilated cardiomyopathy; R/LVD, right/left ventricular dysplasia; NYHA, New York Heart Association functional class of heart failure; SMVT, sustained monomorphic ventricular tachycardia; VF, ventricular fibrillation.